Key Record Dates
| ClinicalTrials.gov Identifier: | NCT04209855 |
|---|---|
| Brief Title: | A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) |
| First Submitted : | December 17, 2019 |
| First Submitted that Met QC Criteria : | December 20, 2019 |
| First Posted : | December 24, 2019 |
| Last Update Submitted that Met QC Criteria : | March 3, 2023 |
| Last Update Posted : | March 6, 2023 |